ReviewThe Journal of antimicrobial chemotherapy2019
Harnessing alternative sources of antimicrobial resistance data to support surveillance in low-resource settings.
Review in The Journal of antimicrobial chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of surveillance systems for AMR in Africa.The Journal of antimicrobial chemotherapy · 2022Pooled it
- The Role of Pharmacovigilance Database in Identifying Antibiotic Resistance and Inappropriate Use: An Analysis of VigiBase Reports From Lower-Middle-Income Countries.Pharmacoepidemiology and drug safety · 2026Article
- A comparison of antibiotic resistance reports in pharmacovigilance databases and conventional surveillance across "One Health".Frontiers in public health · 2026Article
- Mapping the AMR Infection Landscape in Bihar: Implications for Strengthening Policy and Clinical Practice.Antibiotics (Basel, Switzerland) · 2025Article
- A Regional Approach to Strengthening the Implementation of Sustainable Antimicrobial Stewardship Programs in Five Countries in East, Central, and Southern Africa.Antibiotics (Basel, Switzerland) · 2025Article
- Insights of SEDRIC, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium.Wellcome open research · 2025Article
- Capturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia (CAPTURA).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Strengthening antimicrobial resistance surveillance systems: a scoping review.BMC infectious diseases · 2023Article
- Phenotype-genotype correlations among carbapenem-resistant Enterobacterales recovered from four Egyptian hospitals with the report of SPM carbapenemase.Antimicrobial resistance and infection control · 2022Article
- Multidrug Resistance Dynamics in Salmonella in Food Animals in the United States: An Analysis of Genomes from Public Databases.Microbiology spectrum · 2021Article
- One Health drivers of antibacterial resistance: Quantifying the relative impacts of human, animal and environmental use and transmission.One health (Amsterdam, Netherlands) · 2021Article
- Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture.Antimicrobial resistance and infection control · 2021Review
- Filling the gaps in the global prevalence map of clinical antimicrobial resistance.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Surveillance of Resistance to New Antibiotics in an Era of Limited Treatment Options.Frontiers in medicine · 2021Article
- Automating the Generation of Antimicrobial Resistance Surveillance Reports: Proof-of-Concept Study Involving Seven Hospitals in Seven Countries.Journal of medical Internet research · 2020Article
- Antimicrobial Resistance in Agri-Food Chain and Companion Animals as a Re-emerging Menace in Post-COVID Epoch: Low-and Middle-Income Countries Perspective and Mitigation Strategies.Frontiers in veterinary science · 2020Review
- Antimicrobial Stewardship Programs in Resource Constrained Environments: Understanding and Addressing the Need of the Systems.Frontiers in public health · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
One of the most pressing challenges facing the global surveillance of antimicrobial resistance (AMR) is the generation, sharing, systematic analysis and dissemination of data in low-resource settings. Numerous agencies and initiatives are working to support the development of globally distributed microbiology capacity, but the routine generation of a sustainable flow of reliable data will take time to establish before it can deliver a clinical and public health impact. By contrast, there are a large number of pharma- and academia-led initiatives that have generated a wealth of data on AMR and drug-resistant infections in low-resource settings, together with high-volume data generation by private laboratories. Here, we explore how untapped sources of data could provide a short-term solution that bridges the gap between now and the time when routine surveillance capacity will have been established and how this could continue to support surveillance efforts in the future. We discuss the benefits and limitations of data generated by these sources, the mechanisms and barriers to making this accessible and how academia and pharma might support the development of laboratory and analytical capacity. We provide key actions that will be required to harness these data, including: a mapping exercise; creating mechanisms for data sharing; use of data to support national action plans; facilitating access to and use of data by the WHO Global Antimicrobial Resistance Surveillance System; and innovation in data capture, analysis and sharing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.